Examples of using Bindren in English and their translations into Polish
{-}
-
Colloquial
-
Official
-
Medicine
-
Ecclesiastic
-
Ecclesiastic
-
Financial
-
Official/political
-
Programming
-
Computer
Other medicines and BindRen.
BindRen contains colestilan.
How to store BindRen.
BindRen contains the active substance colestilan.
No data on the use of BindRen in pre-dialysis patients are available.
BindRen granules are white cylindrical granules.
If you take too much BindRen, tell your doctor or pharmacist.
BindRen should not be used in children and adolescents.
Patients with seizure disorders were excluded from clinical trials with BindRen.
BindRen 2 g granules: each sachet contains 2 g of colestilan.
Caution should be exercised when prescribing BindRen to patients receiving immunosuppressants.
BindRen alone is not indicated for the control of hyperparathyroidism.
Caution should be exercised when prescribing BindRen to patients also taking anti-seizure medicinal products.
BindRen is not absorbed and is not systemically available.
In very rare cases, intestinal obstruction and ileus/subileus have been observed in patients during treatment with BindRen.
BindRen does not contain calcium and your doctor may prescribe additional calcium tablets.
Talk to your doctor orpharmacist if during your treatment with BindRen, any of the following applies to you.
BindRen tablets are white oval shaped film-coated tablets printed with“BINDREN” in blue ink on one side.
White, oval shaped, film-coated tablet approximately 20.2 mm in length and10.7 mm wide printed with“BINDREN”(in blue ink) on one side.
BindRen does not contain calcium, and has no effect on serum calcium concentrations on treatment for up to one year.
The results of in vitro testing suggest that medicinal products with anionic and/or lipophilic characteristics have a higher potential to bind to BindRen.
BindRen lowered the bioavailability of digoxin by 16% and Cmax by 17%, and the Cmax of enalapril by 27.
If you do become pregnant or you are breast-feeding, andyour doctor decides that you should continue your treatment with BindRen, your doctor may ask you to also take vitamin supplements.
BindRen binds phosphate and bile acid, with the release of chloride which is available for systemic absorption.
Due to the high in vitro binding potential between BindRen and levothyroxine, closer monitoring of thyroid stimulating hormone(TSH) levels in patients receiving BindRen and levothyroxine is recommended.
BindRen did not induce a clinically relevant reduction in folate absorption during clinical studies of up to one year.
Therefore, the use of BindRen is not recommended in patients with severe hepatic impairment see also section 4.4.
However, BindRen did not induce any clinically relevant change in chloride and bicarbonate on treatment for up to one year.
BindRen is not absorbed from the gastrointestinal tract but may affect the bioavailability or absorption rate of other medicinal products.
BindRen is indicated for use in patients with Chronic Kidney Disease(CKD) Stage 5 receiving haemodialysis or peritoneal dialysis.